Lipigon Pharmaceuticals AB (LPGO) — Financial Flexibility Index
Lipigon Pharmaceuticals AB (LPGO) has a Financial Flexibility Index of -1.79x as of December 2025. Free cash flow of Skr-6.38 Million (operating CF Skr-6.38 Million minus capex Skr0.00) represents -2% of total liabilities (Skr3.57 Million). Check LPGO total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lipigon Pharmaceuticals AB Financial Flexibility Index (2018–2025)
Historical Financial Flexibility Index trend for Lipigon Pharmaceuticals AB across 8 annual periods. For the full cash flow conversion analysis, see LPGO cash flow conversion.
Annual Financial Flexibility Index for Lipigon Pharmaceuticals AB (2018–2025)
Year-by-year free cash flow to debt coverage for Lipigon Pharmaceuticals AB. Explore LPGO operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -9.98x | Skr-35.66 Million | Skr-35.77 Million | Skr3.57 Million | ▼ -187.2% |
| 2024 | -3.48x | Skr-24.55 Million | Skr-24.78 Million | Skr7.06 Million | ▼ -25.2% |
| 2023 | -2.78x | Skr-14.32 Million | Skr-14.32 Million | Skr5.16 Million | ▲ +48.5% |
| 2022 | -5.39x | Skr-37.47 Million | Skr-37.47 Million | Skr6.95 Million | ▲ +0.8% |
| 2021 | -5.44x | Skr-35.18 Million | Skr-35.30 Million | Skr6.47 Million | ▼ -44.5% |
| 2020 | -3.77x | Skr-8.51 Million | Skr-8.62 Million | Skr2.26 Million | ▲ +27.9% |
| 2019 | -5.23x | Skr-5.44 Million | Skr-5.56 Million | Skr1.04 Million | ▼ -77.3% |
| 2018 | -2.95x | Skr-3.14 Million | Skr-3.26 Million | Skr1.07 Million | — |